Marc T Abrams

Author:

Marc Abrams

ISBN #:

0139547851

US Patent:

20220364098, Nov 17, 2022

Filed:

Apr 13, 2022

Appl. No.:

17/719821

Inventors:

- Lexington MA, US
Henryk T. DUDEK - Belmont MA, US
Marc ABRAMS - Natick MA, US
Anton TURANOV - Revere MA, US
Bob Dale BROWN - Littleton MA, US

International Classification:

C12N 15/113
C07H 21/02
A61K 31/7125

Abstract:

Oligonucleotides and compositions including the same are disclosed for inhibiting or reducing patatin-like phospholipase domain-containing protein 3 (PNPLA3) gene expression. Methods of making and using the oligonucleotides also are disclosed, particularly uses relating to treating diseases, disorders and/or conditions associated with PNPLA3 expression.

US Patent:

20220340909, Oct 27, 2022

Filed:

Apr 11, 2022

Appl. No.:

17/717174

Inventors:

- Ingelheim am Rhein, DE
Henryk T. DUDEK - Belmont MA, US
Utsav SAXENA - Watertown MA, US
Jihye PARK - Cambridge MA, US
Marc ABRAMS - Natick MA, US
Martin Lee KOSER - Westford MA, US

International Classification:

C12N 15/113
A61P 1/16

Abstract:

Oligonucleotides are provided herein that inhibit KHK expression. Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders and/or conditions associated with KHK expression.

US Patent:

20230000895, Jan 5, 2023

Filed:

Feb 2, 2022

Appl. No.:

17/649781

Inventors:

- Lexington MA, US
Marc ABRAMS - Lexington MA, US

International Classification:

A61K 31/713
A61K 47/02
C12N 15/113

Abstract:

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

US Patent:

20210283164, Sep 16, 2021

Filed:

May 12, 2021

Appl. No.:

17/318864

Inventors:

- Lexington MA, US
Marc ABRAMS - Lexington MA, US

International Classification:

A61K 31/713
A61K 47/02
C12N 15/113

Abstract:

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

US Patent:

20200377882, Dec 3, 2020

Filed:

Mar 28, 2018

Appl. No.:

16/497310

Inventors:

- Lexington MA, US
Marc ABRAMS - Natick MA, US

International Classification:

C12N 15/113
A61P 35/00
A61P 35/02
A61K 39/395
A61K 9/51

Abstract:

Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy. In one aspect, the methods of treatment comprise administering to the subject a therapeutically effective amount of a β-catenin inhibitor and a therapeutically effective amount of an immunotherapeutic agent. Another aspect is directed to pharmaceutical compositions comprising a β-catenin inhibitor for use in treating cancer, wherein the composition is administered in combination with an immunotherapeutic agent. Yet another aspect is directed to a method of potentiating the therapeutic effect of immunotherapy against a cancer using a β-catenin inhibitor, such as a β-catenin nucleic acid inhibitor molecule.

US Patent:

20200338108, Oct 29, 2020

Filed:

Jul 7, 2020

Appl. No.:

16/922007

Inventors:

- Lexington MA, US
Marc ABRAMS - Lexington MA, US

International Classification:

A61K 31/713
A61K 47/02
C12N 15/113

Abstract:

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

US Patent:

20200338109, Oct 29, 2020

Filed:

Jul 7, 2020

Appl. No.:

16/922033

Inventors:

- Lexington MA, US
Marc ABRAMS - Lexington MA, US

International Classification:

A61K 31/713
A61K 47/02
C12N 15/113

Abstract:

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.

US Patent:

20200171069, Jun 4, 2020

Filed:

Feb 14, 2020

Appl. No.:

16/790986

Inventors:

- Lexington MA, US
Marc Abrams - Lexington MA, US

International Classification:

A61K 31/713
C12N 15/113
A61K 47/02

Abstract:

This application relates to potent oligonucleotides useful for reducing HBsAg expression and treating HBV infections.